GSK (NYSE: GSK) moves hepatitis B drug bepirovirsen into EMA marketing review
Rhea-AI Filing Summary
GSK plc reports that the European Medicines Agency has accepted for review a marketing authorisation application for bepirovirsen, an investigational antisense oligonucleotide for adults with chronic hepatitis B. The submission is backed by Phase III B‑Well 1 and B‑Well 2 trials, which met their primary endpoint and showed statistically significant, clinically meaningful functional cure rates versus standard of care.
Chronic hepatitis B affects an estimated 3.2 million people in Europe and more than 250 million worldwide, with current nucleos(t)ide analogue therapies often requiring lifelong treatment and achieving functional cure in only about 1% of patients. Bepirovirsen is designed to target hepatitis B viral RNA, reduce hepatitis B surface antigen, and stimulate the immune system, with trials indicating an acceptable safety and tolerability profile. The data will be presented at a scientific congress and submitted for peer‑reviewed publication in 2026, while bepirovirsen remains unapproved globally.
Positive
- EMA acceptance of bepirovirsen MAA: European regulators have accepted GSK’s marketing application for bepirovirsen in chronic hepatitis B, supported by Phase III B‑Well trials that met their primary endpoint and showed statistically significant, clinically meaningful functional cure rates compared with standard of care.
Negative
- None.
Insights
EMA review of bepirovirsen advances GSK’s late‑stage hepatitis B pipeline.
The acceptance of bepirovirsen’s marketing application by the European Medicines Agency moves this chronic hepatitis B candidate into a formal regulatory review phase. The filing highlights that two pivotal Phase III B‑Well trials met their primary endpoint with statistically significant, clinically meaningful functional cure rates.
Functional cure in hepatitis B is defined as loss of surface antigen and undetectable viral DNA 24 weeks after stopping treatment, a much higher bar than simple viral suppression. Current nucleos(t)ide analogue therapy typically reaches functional cure in only about 1% of patients, underscoring the potential differentiation if these results translate into real‑world practice.
The trials reported an acceptable safety and tolerability profile, and stronger effects in patients with baseline surface antigen ≤1000 IU/ml. Bepirovirsen is also being explored as a backbone for sequential treatment strategies, indicating broader lifecycle planning. The ultimate impact will depend on EMA’s assessment and any future pricing, uptake, and label decisions once regulatory outcomes are known.
FAQ
What did GSK (GSK) announce about bepirovirsen for chronic hepatitis B?
GSK announced that the European Medicines Agency has accepted for review a marketing authorisation application for bepirovirsen to treat adults with chronic hepatitis B. The application is supported by positive Phase III B‑Well trial results showing statistically significant, clinically meaningful functional cure rates.
How effective was bepirovirsen in the Phase III B-Well trials reported by GSK?
Bepirovirsen achieved statistically significant and clinically meaningful functional cure rates in both B‑Well Phase III trials versus standard of care alone. Functional cure rates were especially higher in patients with baseline hepatitis B surface antigen levels ≤1000 IU/ml, while maintaining an acceptable safety and tolerability profile.
What does functional cure mean in GSK’s hepatitis B programme for bepirovirsen?
Functional cure means hepatitis B surface antigen loss and undetectable hepatitis B virus DNA for at least 24 weeks after stopping all treatment. This indicates the immune system controls the infection without ongoing medication, a higher goal than simple viral suppression with lifelong therapy.
How large is the chronic hepatitis B burden relevant to GSK’s bepirovirsen filing?
Chronic hepatitis B affects an estimated 3.2 million people in Europe and more than 250 million worldwide. The disease causes about 1.1 million deaths annually, including roughly 15,000 in Europe, and is responsible for an estimated 56% of liver cancer cases globally.
Is bepirovirsen already approved for chronic hepatitis B treatment?
No, bepirovirsen is currently not approved anywhere in the world. It remains an investigational antisense oligonucleotide, although the European Medicines Agency has accepted its marketing authorisation application based on positive Phase III B‑Well trial results in adults with chronic hepatitis B.
How does bepirovirsen work according to GSK’s 6-K filing?
Bepirovirsen is a triple‑action antisense oligonucleotide designed to target hepatitis B viral mRNA and pregenomic RNA. It inhibits viral genome replication, suppresses hepatitis B surface antigen levels in blood, and stimulates the immune system to increase the chances of a durable, sustained functional cure response.
